X0508 4 2023-08-15 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001855980 Secora Michael C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 0 1 0 0 Chief Financial Officer 1 Class A Common Stock 2023-08-15 4 F 0 4727 9.19 D 838186 D Class A Common Stock 2023-08-15 4 M 0 37500 2.22 A 875686 D Class A Common Stock 2023-08-15 4 S 0 25000 9.2717 D 850686 D Class A Common Stock 2023-08-16 4 M 0 37500 2.22 A 888186 D Class A Common Stock 2023-08-16 4 S 0 25000 8.9007 D 863186 D Stock Option (Right to Buy) 2.22 2030-03-03 Class A Common Stock 0 685177 D Stock Option (Right to Buy) 2.22 2023-08-15 4 M 0 37500 0.00 D 2030-03-03 Class A Common Stock 37500 1485135 D Stock Option (Right to Buy) 2.22 2023-08-16 4 M 0 37500 0.00 D 2030-03-03 Class A Common Stock 37500 1410135 D Stock Option (Right to Buy) 11.14 2032-02-04 Class A Common Stock 0 116684 D Stock Option (Right to Buy) 11.14 2022-02-04 2032-02-04 Class A Common Stock 0 3914 D Stock Option (Right to Buy) 8.55 2033-02-01 Class A Common Stock 0 404857 D Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023. This transaction was executed in multiple trades at prices ranging from $9.14 to $9.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $8.66 to $9.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter. The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. /s/ Jonathan Golightly, attorney-in-fact 2023-08-17